Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
CD8
HPV
TILs
cetuximab
oropharynx
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
13
02
2023
received:
22
10
2022
accepted:
04
03
2023
medline:
7
4
2023
pubmed:
19
3
2023
entrez:
18
3
2023
Statut:
ppublish
Résumé
We sought to characterize early changes in CD8 Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8 One week after cetuximab, five patients (62.5%) had an increase in CD8 Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.
Sections du résumé
BACKGROUND
We sought to characterize early changes in CD8
METHODS
Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8
RESULTS
One week after cetuximab, five patients (62.5%) had an increase in CD8
CONCLUSIONS
Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.
Substances chimiques
Cetuximab
PQX0D8J21J
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1281-1287Subventions
Organisme : NIH HHS
ID : P30-CA046592
Pays : United States
Organisme : NIH HHS
ID : T32DC005356
Pays : United States
Informations de copyright
© 2023 The Authors. Head & Neck published by Wiley Periodicals LLC.
Références
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-1127.
Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study. Lancet. 2019;393:12-18.
Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50:248-254.
Taberna M, Oliva M, Mesia R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. 2019;9:383.
Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22:883-892.
Ferris RL, Moskovitz J, Kunning S, et al. Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer. Clin Cancer Res. 2022;28(7):1335-1344.
Jie H, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol Res. 2017;5(5):408-416.
Jie H, Schuler PJ, Lee SC, et al. CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200-2210.
Park J, Durbeck J, Clark JR, Faden DL. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. Oral Oncol. 2020;111:105024.
Ferris RL, Licitra L, Fayette J, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. Clin Cancer Res. 2019;25(17):5221-5230.
Swiecicki PL, Li P, Bellile E, et al. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. Head Neck. 2020;42:1728-1737.
Hoesli R, Birkeland AC, Rosko AJ, et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol. 2018;77:83-89.
Mann JE, Smith JD, Birkeland AC, et al. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunol Immunother. 2019;68(2):213-220.
Birkeland AC, Foltin SK, Michmerhuizen NL, et al. Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol. 2017;68:5-8.
Birkeland AC, Yanik M, Tillman BN, et al. Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2016;142(6):559-567.
Tillman BN, Yanik M, Birkeland AC, et al. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. Head Neck. 2016;38:E1646-E1652.
Heft Neal ME, Bhangale AD, Birkeland AC, et al. Prognostic significance of oxidation pathway mutations in recurrent laryngeal squamous cell carcinoma. Cancers (Basel). 2020;12(11):3081.
Heft Neal ME, Gensterblum-Miller E, Bhangale AD, et al. Integrative sequencing discovers an ATF1-motif enriched molecular signature that differentiates hyalinizing clear cell carcinoma from mucoepidermoid carcinoma. Oral Oncol. 2021;117:105270.
Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243-259.
Lechner A, Schlosser H, Rothschild SI, et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget. 2017;8:44418-44433.
Canning M, Guo G, Yu M, et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol. 2019;7:52.
Fakhry C, Lacchetti C, Rooper LM, et al. Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the College of American Pathologists guideline. J Clin Oncol. 2018;36(31):3152-3161.
Nauta IH, Rietbergen MM, van Bokhoven AAJD, et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in The Netherlands and the importance of additional HPV DNA testing. Ann Oncol. 2018;29:1273-1279.
Villacampa EG, Larsson L, Mirzazadeh R, et al. Genome-wide spatial expression profiling in formalin-fixed tissues. Cell Genomics. 2021;1(3):100065.
Haring CT, Dermody SM, Yalamanchi P, et al. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma. Oral Oncol. 2022;126:105776.
Flach S, Howarth K, Hackinger S, et al. Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer. 2022;126(8):1186-1195.
Weidhaas JB, Harris J, Schaue D, et al. The KRAS-variant and cetuximab response in head and neck squamous cell cancer. A secondary analysis of a randomized clinical trial. JAMA Oncol. 2017;3(4):483-491.